These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29191321)

  • 1. Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF.
    Tsujimoto T; Kajio H
    J Am Coll Cardiol; 2017 Dec; 70(22):2739-2749. PubMed ID: 29191321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction.
    Tsujimoto T; Kajio H
    Int J Cardiol; 2018 Jul; 263():69-74. PubMed ID: 29661477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease.
    Tsujimoto T; Kajio H
    Int J Cardiol; 2018 Mar; 255():111-117. PubMed ID: 29307549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
    Tsujimoto T; Kajio H
    Eur J Prev Cardiol; 2018 Aug; 25(12):1268-1277. PubMed ID: 29808753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
    Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
    Sandesara PB; Hammadah M; Samman-Tahhan A; Kelli HM; O'Neal WT
    Clin Cardiol; 2017 Sep; 40(9):692-696. PubMed ID: 28444995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
    Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
    Hegde SM; Claggett B; Shah AM; Lewis EF; Anand I; Shah SJ; Sweitzer NK; Fang JC; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2017 Sep; 136(11):982-992. PubMed ID: 28637881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.
    O'Neal WT; Sandesara P; Hammadah M; Venkatesh S; Samman-Tahhan A; Kelli HM; Soliman EZ
    Am J Cardiol; 2017 Jun; 119(11):1785-1790. PubMed ID: 28395886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
    O'Neal WT; Sandesara PB; Samman-Tahhan A; Kelli HM; Hammadah M; Soliman EZ
    Eur J Prev Cardiol; 2017 Jul; 24(11):1212-1219. PubMed ID: 28482692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte count and the risk of adverse outcomes in patients with HFpEF.
    Zhu Z; Zhou S
    BMC Cardiovasc Disord; 2021 Jul; 21(1):333. PubMed ID: 34233611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
    Rahimi G; Tecson KM; Elsaid O; McCullough PA
    Am J Cardiol; 2021 Mar; 142():91-96. PubMed ID: 33279481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waist to height ratio is associated with an increased risk of mortality in Chinese patients with heart failure with preserved ejection fraction.
    Chen J; Li M; Hao B; Cai Y; Li H; Zhou W; Song Y; Wang S; Liu H
    BMC Cardiovasc Disord; 2021 May; 21(1):263. PubMed ID: 34049494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Threshold body mass index and sex-specific waist circumference for increased risk of heart failure with preserved ejection fraction.
    Campbell DJ; Gong FF; Jelinek MV; Castro JM; Coller JM; McGrady M; Boffa U; Shiel L; Liew D; Stewart S; Owen AJ; Krum H; Reid CM; Prior DL
    Eur J Prev Cardiol; 2019 Oct; 26(15):1594-1602. PubMed ID: 31104485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Philips S; Mullens W; Nijst P; Martens P; Fang JC; Drazner MH; Tang WHW; Pandey A
    Eur J Heart Fail; 2019 May; 21(5):634-642. PubMed ID: 30714658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Heart Rate and Beta-Blocker Use in Sinus Rhythm in Patients with Heart Failure and Preserved Ejection Fraction.
    Li S; Li X
    High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):405-411. PubMed ID: 31625118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction.
    Sandesara PB; O'Neal WT; Kelli HM; Samman-Tahhan A; Hammadah M; Quyyumi AA; Sperling LS
    Diabetes Care; 2018 Jan; 41(1):150-155. PubMed ID: 29051160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.